Dr Mayfong Mayxay
|Technology Exchange:||Medical statistics|
|Scientific Themes:||Tropical Medicine & Global Health and Clinical Trials & Epidemiology|
|Keywords:||Dengue, Japanese encephalitis and Antimalarial drug resistance|
Mayfong Mayxay has been working for LOMWRU since the establishment of the Unit in 2000. He has led clinical trials of antimalarials and other field clinical research in Laos since 2000 and between 2002 and 2006, under the supervision of Prof. Nick White and Prof. Paul Newton, he carried out his Wellcome fellowship training in clinical tropical medicine with the research entitled “Clinical and laboratory studies to guide Lao national antimalarial drug policy” which was associated with Mahidol and Oxford Universities. The results from his research had led to the change of the Lao national policy for uncomplicated falciparum malaria treatment from chloroquine and sulphadoxine-pyrimethamine to ACTs (artemether-lumefantrine) in 2005.
Mayfong is the Head of the Field Research of LOMWRU and Vice-Dean for Research at the Faculty of Postgraduate Studies and Associate Professor, Lao University of Health Sciences. He has also been an Honorary Visiting Research Fellow in Tropical Medicine at Oxford since 2009. His particular research interests include antimalarial drug resistance, causes of fever, dengue, rickettsial infections, Japanese encephalitis virus infection, and infantile beriberi.
There are no collaborations listed for this principal investigator.
There are no publications listed for this principal investigator.